WARF: P130274US02

Treating Fungal Infections with New Forazoline Compounds


Timothy Bugni, Thomas Wyche, David Andes, Douglas Braun

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing compounds isolated from a sea squirt bacterium that could be effective against Candida and other fungi.
OVERVIEWFungal infections range in severity from common athlete’s foot to life-threatening illness. Treatment can be very expensive. The cost of treating systemic Candida yeast infections exceeds $31,000 per patient in the United States. This fungus is responsible for afflictions like diaper rash, vaginal yeast infection and oral thrush.

Finding new agents to fight Candida and other fungal infections could be globally beneficial and profitable.
THE INVENTIONUW–Madison researchers have developed antifungal compounds isolated from Actinomadura, a bacterium found in a species of sea squirt. After extensive chemical isolation and characterization, the researchers identified a new class of compounds called ‘Forazolines’ that possess antifungal activity. Forazoline A was shown to be effective against Candida albicans in a mouse model.
  • Candida infections cost more than $2.6 billion worldwide.
  • The global market for antifungal agents is expected to grow to $11.3 billion in 2014.
  • Fresh antifungals are needed to combat the crisis of drug-resistant strains.
  • Developing new antifungal agents (cream, nasal spray, syrup, etc.) against Candida yeast and potentially other strains
  • Proven effective
  • Forazoline is a natural product.
  • Could be safely and flexibly administered to patients
STAGE OF DEVELOPMENTIn a mouse model of C. albicans infection, Forazoline A was shown to reduce kidney fungal load by a log after eight hours of treatment. No toxic effects were observed at the concentrations used.
Contact Information
For current licensing status, please contact Rafael Diaz at or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.